These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 17287733

  • 21. New pharma-biotech company formation in India.
    Saberwal G.
    Nat Biotechnol; 2006 May; 24(5):499-501. PubMed ID: 16680124
    [No Abstract] [Full Text] [Related]

  • 22. Europe's biotech renaissance.
    Senior M.
    Nat Biotechnol; 2020 Apr; 38(4):408-415. PubMed ID: 32265563
    [No Abstract] [Full Text] [Related]

  • 23. Investigating investment in biopharmaceutical R&D.
    Carter PH, Berndt ER, DiMasi JA, Trusheim M.
    Nat Rev Drug Discov; 2016 Oct; 15(10):673-4. PubMed ID: 27616295
    [Abstract] [Full Text] [Related]

  • 24. Evolution and future of biopharmaceuticals.
    Health Aff (Millwood); 2006 Oct; 25(5):1270. PubMed ID: 16966722
    [No Abstract] [Full Text] [Related]

  • 25. The challenges of product- and process-related impurities to an evolving biopharmaceutical industry.
    Bracewell DG, Smales CM.
    Bioanalysis; 2013 Jan; 5(2):123-6. PubMed ID: 23330553
    [No Abstract] [Full Text] [Related]

  • 26. Biotech round the world: focus on Canada.
    Biotechnol J; 2008 Jul; 3(7):848-51. PubMed ID: 18624341
    [No Abstract] [Full Text] [Related]

  • 27. Deal watch: Biopharma deal-making in 2015: changing the pharma landscape.
    Micklus A, Muntner S.
    Nat Rev Drug Discov; 2016 Feb; 15(2):78-9. PubMed ID: 26837586
    [No Abstract] [Full Text] [Related]

  • 28. The biotechnology industry: What's next?
    Guertin PA.
    Biotechnol J; 2009 Aug; 4(8):1124-31. PubMed ID: 19685466
    [No Abstract] [Full Text] [Related]

  • 29. Silent running: the race to the clinic.
    Nature; 2006 Aug 10; 442(7103):614-5. PubMed ID: 16900171
    [No Abstract] [Full Text] [Related]

  • 30. Biopharma deal-making in 2016.
    Micklus A, Muntner S.
    Nat Rev Drug Discov; 2017 Mar 10; 16(3):161-162. PubMed ID: 28209988
    [No Abstract] [Full Text] [Related]

  • 31. How the street sees biotech.
    Lashinsky A.
    Fortune; 2003 Jun 09; 147(11):86. PubMed ID: 12800576
    [No Abstract] [Full Text] [Related]

  • 32. China's biotech is starting to bloom.
    Stipp D.
    Fortune; 2002 Sep 02; 146(4):126-30, 132, 134. PubMed ID: 12195673
    [No Abstract] [Full Text] [Related]

  • 33. Biotechnology in Ireland: hard work, money and the brain gain.
    O'Neill MF.
    Drug Discov Today; 2007 Feb 02; 12(3-4):108-11. PubMed ID: 17275730
    [No Abstract] [Full Text] [Related]

  • 34. Greenovation biotech GmbH.
    Arzneimittelforschung; 2008 Feb 02; 58(1):48-9. PubMed ID: 18368951
    [No Abstract] [Full Text] [Related]

  • 35. Biotech patenting slows in 2004.
    Lawrence S.
    Nat Biotechnol; 2005 Oct 02; 23(10):1198. PubMed ID: 16211048
    [No Abstract] [Full Text] [Related]

  • 36. Nasdaq dilutes its biotech index.
    Dorey E.
    Nat Biotechnol; 2004 Jan 02; 22(1):9. PubMed ID: 14704690
    [No Abstract] [Full Text] [Related]

  • 37. Can China's supply of scientific talent keep up with demand?
    Wong G.
    Nat Biotechnol; 2008 Feb 02; 26(2):243-4. PubMed ID: 18259182
    [Abstract] [Full Text] [Related]

  • 38. Big pharma swallows biotech's pride.
    Huggett B.
    Nat Biotechnol; 2008 Sep 02; 26(9):955-6. PubMed ID: 18779785
    [No Abstract] [Full Text] [Related]

  • 39. Biotech at the beauty counter.
    Nasto B.
    Nat Biotechnol; 2007 Jun 02; 25(6):617-9. PubMed ID: 17557090
    [No Abstract] [Full Text] [Related]

  • 40. Flexibility--the guiding principle for antibody manufacturing.
    Carson KL.
    Nat Biotechnol; 2005 Sep 02; 23(9):1054-8. PubMed ID: 16151390
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.